Modulation of Splicing by Single-Stranded Silencing RNAs

Nucleic Acid Therapeutics

Volumn 25, Issue 3, 2015, Pages 113-120

  Liu, Jing ^a   Hu, Jiaxin ^a   Hicks, Jessica A ^a   Prakash, Thazha P ^b   Corey, David R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ARGONAUTE 2 PROTEIN; DYSTROPHIN; ISOPROTEIN; PHOSPHOROTHIOIC ACID; SINGLE STRANDED RNA; SINGLE STRANDED SILENCING RNA; UNCLASSIFIED DRUG; RNA;

ARTICLE; BECKER MUSCULAR DYSTROPHY; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOPLASM; DUCHENNE MUSCULAR DYSTROPHY; ENDOPLASMIC RETICULUM; EXON; EXON SKIPPING; FIBROBLAST; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; QUALITY OF LIFE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA SPLICING; RNA STRUCTURE; STOP CODON; CELL CULTURE; GENETICS;

MAMMALIA;

CELLS, CULTURED; HUMANS; RNA; RNA INTERFERENCE; RNA SPLICING;

EID: 84929858672     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2014.0527     Document Type: Article

References (38)

1. Gagnon KT and DR Corey (2012). Argonaute and the Nuclear RNAs: new pathways for RNA-mediated control of gene expression. Nucleic Acid Ther 22:3-16.
2. Li LC (2014). Chromatin remodeling by small RNA machinery in mammalian cells. Epigenetics 9:45-52.
3. Castel SE and RA Martienssen (2013). RNA Interference in the nucleus: roles for small RNAs in transcription, epigenetics, and beyond. Nat Rev Genet 14:100-112.
4. Schraivogel D and G Meister (2014). Import routes and nuclear functions of argonaute and other small RNA-silencing proteins. Trends Biochem Sci 39:420-431.
5. White E, M Schacklow, K Kamieniarz-Gdula, NJ Proudfoot and M Gullerova (2014). Human nuclear dicer restricts the deleterious accumulation of endogenous double-stranded RNA. Nat Struc Mol Biol 21:552-559.
6. Ross JP and Kassir Z (2014). The varied roles of nuclear argonaute-small RNA complexes and avenues for therapy. Mol Ther Nucl Acids 3:e203.
7. Matsui M, H Zhang, Y Chu, KT Gagnon, M Manoharan, DR Corey and BA Janowski (2013). A Network of noncoding RNAs links transcription of inflammatory pathway genes COX-2 and PLAG24A. Nucleic Acids Res 41:10086-10109.
8. Weinberg MS and KV Morris (2013). Long non-coding RNA targeting and transcriptional de-repression. Nucleic Acid Ther 23:9-4.
9. Place RF, LC Li, D Pookot, EJ Noonan and R Dahiya (2001). MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci (USA) 105:1608-613.
10. Kim DH, P Saetrom, O Snove and JJ Rossi (2008). MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci 105:16230-16235.
11. Younger ST and DR Corey (2011). Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters. Nucl Acids Res 39:5682-5691.
12. Robb GB, KM Brown, J Khurana and TM Rana (2005). Specific and potent RNAi in the nucleus of human cells. Nature Struct Mol Biol 12:133-37.
13. Orht T, J Muetze, P Svoboda and P Schwille, P (2012). Intracellular localization and routing of miRNA and RNAi pathway components. Curr Top Med Chem 12:79-8.
14. Gagnon KT, L Li, Y Chu, BA Janowski and DR Corey (2014). RNAi factors are present and active in mammalian cell nuclei. Cell Reports 6:211-221.
15. Veltrop M and A Aartsma-Rus (2014). Antisense-mediated exon skipping: taking advantage of a trick from Mother Nature to treat rare genetic diseases. Exper Cell Res 325:50-55.
16. Jarver P, L O'Donovan and MJ Gait (2014). A chemical view of oligonucleotides for exon skipping and related drug applications. Nucleic Acid Ther 24:37-47.
17. Rigo F, PP Seth and CF Bennett (2014). Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects. Adv Exp Med Biol 825:303-352.
18. Battsche E and M Ameyar-Zazoua (2014). The influence of argonaute proteins on alternative RNA splicing. Wiley Interdiscip Rev. RNA 6:141-156.
19. Liu J, J Hu, and DR Corey (2012). Expanding the action of duplex RNAs into the nucleus: redirecting alternative splicing. Nucl Acids Res 40:1240-1250.
20. Allo M, V Buggiano, JP Fededa, E Petrillo, I Schor, M de la Mata, E Agirre, M Plass, E Eyras, et al. (2009). Control of alternative splicing through siRNA-mediated transcriptional gene silencing. Nat Struc Mol Biol 16:717-724.
21. Ameyar-Zazoua M, C Rachez, M Souidi, P Robin, L Fritsch, R Young, N Morozova, R Fenouil, N Descostes, et al. (2014). Control of alternative splicing through siRNA-mediated transcriptional gene silencing. Nat Struc Mol Biol 19:998-1004.
22. Allo M, E Agirre, S Bessonov, P Bertucci, L Gomez Acuna, V Buggiano, N Bellora, B Singh, E Petrillo, et al. (2104). Argonaute-1 binds transcriptional enhances and controls constitutive and alternative splicing in human cells. Proc Natl Acad Sci (USA) 111:15622-15629.
23. Lima WF, TP Prakash, HM Murray, GA Kinberger, W Li, AE Chappell, CS Li, SF Murray, H Gaus, et al. (2012). Single-stranded siRNAs activate RNAi in animals. Cell 150: 883-894.
24. Prakash TP, WF Lima, HM Murray, S Elbashir, W Cantley, D Foster, M Jayaraman, AE Chappell, M Manoharan, EE Swayze and ST Crooke. (2013). Lipid nanoparticles improve activity of single-stranded siRNA and gapmer antisense oligonucleotides in animals. ACS Chem Biol 8:1402-1406.
25. Yu D, H Pendergraff, J Liu, HB Kordasiewicz, DW Cleveland, E Swayze, W Lima, ST Crooke, T Prakash and DR Corey. (2012). Single-stranded RNAs that function through RNAi are potent and allele-selective inhibitors of huntingtin expression. Cell 150:895-908.
26. Hu J, J Lui, D Yu, Y Aiba, S Lee, H Pendergraff, J Boubaker, JW Arates, C Lagier-Tourenne, et al. (2014). Exploring the effect of sequence length and composition on allele-selective inhibition of human huntingtin expression by single-stranded silencing RNAs. Nucleic Acid Ther 24:199-209.
27. Liu J, D Yu, Y Aiba, H Pendergraff, EE Swayze, WF Lima, TP Prakash and DR Corey. (2013). ss-siRNAs allele-selectively inhibit ataxin-3 expression: Multiple mechanisms for an alternative gene silencing strategy. Nucl Acids Res 41: 9570-9583.
28. Hu J, J Liu, KJ Narayannair, JG Lackey, S. Kuchimanchi, KG Rajeev, M Manoharan, EE Swayze, WF Lima, et al. (2014). Allele-selective inhibition of mutant atrophin-1 expression by duplex and single-stranded RNAs. Biochemistry 53,4510-4518.
29. Matsui M, TP Prakash and DR Corey. (2013). Transcriptional silencing by single-stranded RNAs targeting a noncoding RNA that overlaps a gene promoter. ACS Chem Biol 8:122-126.
30. Aartsma-Rus A, M Bremmer-Bout, AMM Janson, JT Dunnen, GTB van Ommen and JCT van Deutekom. (2002). Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscl Disord 12:S71-S77.
31. Arechavala-Gomeza V, IR Graham, LJ Popplewell, AM Adams, A Aartsma-Rus, M Kinali, JE Morgan, JC Van Deutekom, SD Wilton, G Dickson and F Muntoni. (2007). Comparative analysis of antisense oligonucleotide sequences for targeting skipping of exon 5 during dystrophin pre-mRNA splicing in human muscle. Hum Mol Gene Ther 18:798-810.
32. van Deutekom JC, AA Janson, IB Ginjaar, WS Frankhuizen, A Aartsma-Rus, M Bremmer-Bout, JT den Dunnen, K Koop, AJ van der Kooi, et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. New Eng J Med 375:2677-2686.
33. Lu QL, T Yokota, S Takeda, L Garcia, F Muntoni and T Partridge. (2011). The status of exon skipping as a therapeutic approach to Duchennes muscular dystrophy. Mol Ther 19:9-15.
34. Kole R and BJ Leppert (2012). Targeting mRNA splicing as a potential treatment for Duchenne muscular dystrophy. Discov Med 14:59-69.
35. Voit T, H Topaloglu, V Straub, F Muntoni, N Deconinck, G Campion, SJ de Kimpe, M Eagle, M Guglieri, et al. (2014). Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory randomised, placebo-controlled phase 2 study. Lancet Neurol 13:987-996.
36. Hoffman EP and EM Mcnally. (2014). Exon-skipping therapy: a roadblock, detour, or a bump in the road. Sci Transl Med 6:230.
37. Liu J, MA Carmell, FV Rivas, CG Marsden, JM Thomsen, JJ Song, SM Hammond, L Joshua-Tor and GJ Hannon. (2004). Argonaute 2 is the catalytic engine of RNAi. Science 305:1437-1441.
38. Wang Y, S Juranek, H Li, G Sheng, T Tuschl and DJ Patel. (2008). Structure of an argonaute silencing complex with a seed-containing guide DNA and target RNA duplex. Nature 456:921-926.